Advancing supplement science: challenges and solutions

Cohen, Pieter A.; Venhuis, Bastiaan J.; Brandt, Simon D.

doi:10.1002/dta.1953

Cited by 6 publications

(5 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 Supplements are treated differently than pharmaceutical drugs. 6 The FDA requires safety/efficacy documentation prior to market entry for drugs, but DS are not held to the same standard. 3 Dietary Supplements Health and Education Act allow DS to be regulated as food not 'drugs' with minimal oversight from the FDA.…”

Section: Nutrition and Dietary Supplementsmentioning

confidence: 99%

“…3 FDA can remove DS from the market if it provides a danger to public health. 6 By law, pharmaceutical companies are required to meet quality standards established by United States Pharmacopeia (USP), whereas manufacturers of DS are only required to exceed USP standards if the manufacturer reports following USP standards. 6 Simply, DS do not have to be a certain quality.…”

Section: Nutrition and Dietary Supplementsmentioning

confidence: 99%

See 1 more Smart Citation

Abstracts

2019

Journal of Investigative Medicine

View full text Add to dashboard Cite

Section: Nutrition and Dietary Supplementsmentioning

confidence: 99%

Section: Nutrition and Dietary Supplementsmentioning

confidence: 99%

Abstracts

2019

Journal of Investigative Medicine

View full text Add to dashboard Cite

“… 50 To date, despite a better understanding of the pathogenesis of AD and MCI and the concept of disease, disease-modifying treatments are lacking. Supplements are commonly regarded as safe 51 and advantageous for enhancing cognitive capacity among older individuals. 52 Deepening the study of supplements may be an important breakthrough in improving cognitive function in patients with AD and MCI.…”

Section: Discussionmentioning

confidence: 99%

Supplements for cognitive ability in patients with mild cognitive impairment or Alzheimer’s disease: a protocol for systematic review and network meta-analysis of randomised controlled trials

Zhang,

Li,

Yin

et al. 2024

BMJ Open

View full text Add to dashboard Cite

IntroductionConsidering the increasing incidence of Alzheimer’s disease (AD) and mild cognitive impairment (MCI) worldwide, there is an urgent need to identify efficacious, safe and convenient treatments. Numerous investigations have been conducted on the use of supplements in this domain, with oral supplementation emerging as a viable therapeutic approach for AD or MCI. Nevertheless, given the multitude of available supplements, it becomes imperative to identify the optimal treatment regimen.Methods and analysisEight academic databases and three clinical trial registries will be searched from their inception to 1 June 2023. To identify randomised controlled trials investigating the effects of supplements on patients with AD or MCI, two independent reviewers (X-YZ and Y-QL) will extract relevant information from eligible articles, while the risk of bias in the included studies will be assessed using the Rob 2.0 tool developed by the Cochrane Collaboration. The primary outcome of interest is the overall cognitive function. Pair-wise meta-analysis will be conducted using RevMan V.5.3, while network meta-analysis will be carried out using Stata 17.0 and ADDIS 1.16.8. Heterogeneity test, data synthesis and subgroup analysis will be performed if necessary. The GRADE system will be employed to assess the quality of evidence. This study is scheduled to commence on 1 June 2023 and conclude on 1 October 2023.Ethics and disseminationEthics approval is not required for systematic review and network meta-analysis. The results will be submitted to a peer-reviewed journal or at a conference.Trial registration numberPROSPERO (CRD42023414700).

show abstract

“…Therefore, several actions are on-going worldwide to protect the public from these malignant activities. Recently, the number of global and local inspections on food supplements has been increased and official controls in the respective chain are performed regularly [12]. In Belgium, the Federal Agency for the Safety of the Food Chain (FASFC) in collaboration with the Federal Agency for Medicines and Healthcare Products (FAMHP) and the federal law enforcement, are responsible for this task and upon their request questionable food supplements suspected to contain illegal pharmaceutical preparations or research chemicals are regularly subjected to analysis in our Official Medicines Control Laboratory (OMCL).…”

mentioning

confidence: 99%

Identification and Quantification Methodology for the Analysis of Suspected Illegal Dietary Supplements: Reference Standard or no Reference Standard, that the Question

Vanhee¹,

Tuenter²,

Kamugisha³

et al. 2018

J Forensic Toxicol Pharmacol

View full text Add to dashboard Cite

The consumption of food supplements has become a billion dollar business that has proliferated across the globe. Consequently this also resulted in the increase of adulterations by the illegal addition of medicinal substances or their analogues. The vast majority of the pharmaceutical substances encountered in those samples belong to the three 'classical' categories, including sexual enhancers (e.g. PDE-5 inhibitors and flibanserine), weight loss enhancers occasionally accompanied with an anti-depressant (e.g. sibutramine, phenolphthalein, sibutramine and fluoxetine or venlafaxine) and sports performance enhancers (e.g. selective androgen receptors (SARMs) and anabolic-androgenic steroids (AAS)). Recently also chemicals belonging to the class of pharmaceutical cognition enhancers or nootropics are gaining popularity amongst the general public. While for many of the classical categories reference standards are available to unambiguously confirm the identity of a pharmaceutical product, for several molecules, including some nootropics, no certified reference material is available. Hereby, with the example of an adrafinil containing food supplements, we show how, by utilising multiple methodologies, we were able to come to identification and subsequent quantification when no certified reference standard was available. Furthermore, in 2017 already several food supplements analysed by our lab were positive for the presence of nootropic substances, indicating that these compounds are really gaining popularity amongst the general public.

show abstract

Advancing supplement science: challenges and solutions

Cited by 6 publications

References 37 publications

Abstracts

Abstracts

Supplements for cognitive ability in patients with mild cognitive impairment or Alzheimer’s disease: a protocol for systematic review and network meta-analysis of randomised controlled trials

Identification and Quantification Methodology for the Analysis of Suspected Illegal Dietary Supplements: Reference Standard or no Reference Standard, that the Question

Contact Info

Product

Resources

About